Sagimet Biosciences (SGMT) Total Non-Current Liabilities (2022 - 2023)
Sagimet Biosciences (SGMT) posted quarterly Total Non-Current Liabilities of $5.0 million for Q3 2023, down 4.5% quarter-over-quarter from $5.3 million in Q2 2023.
Sagimet Biosciences (SGMT) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Sagimet Biosciences' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $5.0 million for Q3 2023.
- In Q3 2023, Total Non-Current Liabilities changed N/A year-over-year to $5.0 million; the TTM figure through Sep 2023 stood at $5.0 million (changed N/A YoY), while the FY2022 annual figure was $5.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q3 2023 stood at $5.0 million, down from $5.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $5.4 million in Q4 2022, with the low at $5.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 5.05 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Dec 31, 2022 | 5.36 Mn |